This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Adult-onset IBD linked to higher mortality While the onset of inflammatory bowel disease (ulcerative ... (17 May 2019)
Children who walk to school less likely to ... Children who regularly walk or cycle to school are less likely ... (20 May 2019)
Women with sleep apnoea are more likely to ... A study of more than 19,000 people has found that women with ... (20 May 2019)
Passion trumps love for sex in relationships When women distinguish between sex and the relational and ... (17 May 2019)
Inflammatory Bowel Disease During Childhood ... A new study revealed an increased risk of cancer and early death ... (13 May 2019)
Friday, 03 August 2018 13:13

Ketamine Has Potential Therapeutic Role in Adolescents with Treatment-Resistant Depression Featured

Rate this item
(0 votes)

A new study has shown a significant average decrease in the Children’s Depression Rating Scale (42.5%) among adolescents with treatment-resistant depression (TRD) who were treated with intravenous ketamine.

The study, which demonstrated the tolerability and potential role of ketamine as a treatment option for adolescents with TRD, is published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Child and Adolescent Psychopharmacology website.

The article entitled “Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study” was coauthored by Kathryn Cullen, MD, University of Minnesota Medical School, Minneapolis, and a team of researchers from University of Minnesota, Hennepin County Medical Center (Minneapolis, MN), and Mayo Clinic (Rochester, MN).

The study participants were young adults aged 12-18 years who had failed two previous trials of antidepressants. They received six ketamine infusions over 2 weeks. The treatment was well tolerated. Based on the Children’s Depression Rating Scale scores, 38% of participants met the criteria for clinical response and remission.

“The field is excited about a potential new agent for adolescents with treatment resistant depression. We look forward to additional studies of ketamine to validate this treatment,” saysHarold S. Koplewicz, MD, Editor in Chief of theJournal of Child and Adolescent Psychopharmacologyand President of the Child Mind Institute in New York.


Source: Mary Ann Liebert, Inc., Publishers
Full bibliographic information
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Journal of Child and Adolescent Psychopharmacology. 

Read 597 times Last modified on Saturday, 04 August 2018 07:13

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…